The UCLA CTSI is an academic-clinical-community partnership designed to accelerate scientific discoveries and clinical breakthroughs to improve health in the most populous and diverse county in the United States. An ethnic, economic and cultural mosaic, Los Angeles County provides challenges for health and disease research that few counties replicate. Our mission is to create a borderless clinical and translational research institute that brings UCLA innovations and resources to bear on the greatest health needs of Los Angeles. We are aligning our strengths to support clinical and translational science that is in full partnership with and responsive to the needs of our Los Angeles community. Our UCLA CTSI is bridging disciplinary and institutional boundaries to create transdisciplinary teams focused on the greatest opportunities as well as the greatest needs in our region. CTSA funding will accelerate our progress in achieving our transformative mission and allow the UCLA CTSI to make significant contributions to the goals of the national CTSA consortium. To accomplish our mission the UCLA CTSI has established five goals: 1) Create an academic home for clinical and translational science that integrates and builds on the many strengths of UCLA and its partners, 2) Build transdisciplinary research teams to accelerate and translate discovery to improve health, 3) Transform educational and career development programs to promote the next generation of clinician investigators and translational scientists, 4) Advance and expand strong bi-directional academic-community partnerships to ensure that new scientific discovery is relevant to community needs and, 5) Serve as a national resource for collaborative research through regional, statewide and national CTSA consortia. In transforming our research enterprise, the UCLA-CTSI is guided by core principles including team science, flexible research infrastructure and community engagement. The UCLA CTSI is built on a strong foundation of success in discovery, translational science, community engagement and health services research. Unique resources of the UCLA CTSI include close collaborations with world-leading centers, institutes, schools and programs with which we will co-fund and conduct our clinical and translational science. With institutional support in the pre-award period, the UCLA CTSI has taken significant strides to transform its approach to clinical and translational biomedical research. CTSA funding will accelerate our progress in achieving our transformative mission and allow the UCLA CTSI to make significant contributions to the goals of the national CTSA consortium.

Public Health Relevance

Los Angeles County offers an ideal environment for developing effective translational strategies and faces challenges including subpopulations who are underrepresented in all phases of research. Further its fragmented health care systems require implementation, dissemination and diffusion research for scientific discovery to have a large social impact. As the US population becomes more diverse in the 21^'Century, our experiences and successes will offer a model for health improvement nationwide.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR000124-04S1
Application #
8915800
Study Section
Special Emphasis Panel (ZRR1-CR-3 (01))
Program Officer
Talbot, Bernard
Project Start
2011-06-01
Project End
2016-02-29
Budget Start
2014-09-06
Budget End
2015-03-05
Support Year
4
Fiscal Year
2014
Total Cost
$113,190
Indirect Cost
$39,690
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Dai, Xinghong; Gong, Danyang; Lim, Hanyoung et al. (2018) Structure and mutagenesis reveal essential capsid protein interactions for KSHV replication. Nature 553:521-525
Shin, S S; Modongo, C; Zetola, N M et al. (2018) High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana. Int J Tuberc Lung Dis 22:366-370
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Freyvert, Yevgeniy; Yong, Nicholas Au; Morikawa, Erika et al. (2018) Engaging cervical spinal circuitry with non-invasive spinal stimulation and buspirone to restore hand function in chronic motor complete patients. Sci Rep 8:15546
Sims, Jessica D; Taguiam, Jan Michael; Alonso-Valenteen, Felix et al. (2018) Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. J Control Release 271:127-138
Pothoulakis, Charalabos; Torre-Rojas, Monica; Duran-Padilla, Marco A et al. (2018) CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. Int J Cancer 142:334-346
Tanjaya, Justine; Lord, Elizabeth L; Wang, Chenchao et al. (2018) The Effects of Systemic Therapy of PEGylated NEL-Like Protein 1 (NELL-1) on Fracture Healing in Mice. Am J Pathol 188:715-727
Rajamani, Uthra; Gross, Andrew R; Hjelm, Brooke E et al. (2018) Super-Obese Patient-Derived iPSC Hypothalamic Neurons Exhibit Obesogenic Signatures and Hormone Responses. Cell Stem Cell 22:698-712.e9
Jia, Dongyu; Nagaoka, Yoshiko; Katsumata, Makoto et al. (2018) Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep 8:12394
Swendeman, Dallas; Fehrenbacher, Anne E; Roy, Soma et al. (2018) Gender disparities in depression severity and coping among people living with HIV/AIDS in Kolkata, India. PLoS One 13:e0207055

Showing the most recent 10 out of 2215 publications